Abbott to Open Rs 450-Crore Nutrition Products Plant in Gujarat
New Delhi: Global healthcare major Abbott will on Thursday open its manufacturing plant for nutrition products in Gujarat where it has invested Rs 450 crore as part of its plans to strengthen presence in India.
With the opening of the new plant, the company is also adding 400 new jobs taking its overall employee count in the nutrition segment in India to 1,150.
"The manufacturing plant reflects our commitment to India. Earlier, we had set up an R&D centre in Bengaluru in May 2012. This will take our employee strength in the country to around 1,150," Abbott Nutrition India managing director Amal Kelshikar told PTI.
The new facility is the company's third manufacturing site in India, with two others being pharmaceutical units in Baddi and Goa. The new plant will be formally inaugurated by state Chief Minister Anandiben Patel.
Mr Kelshikar said the new plant will have a manufacturing capacity of 40 million pounds per annum and the company could consider enhancing it or adding a new plant when the current capacity is fully utilised.
 Stressing on the company's focus on India, Abbott Global Nutrition executive vice president John Landgraf said, "We believe that our ongoing commitment represents an investment in a healthier India by providing high-quality nutritional products that will meet the health needs of local consumers."
When asked if the company was also looking for taking the inorganic route for growth in India, Mr Landgraf said the company is always open to the idea but did not elaborate.
"Abbott plans to locally source up to 80 per cent of ingredients for new plant in India and is developing programme to provide infrastructure and training to dairy farmers," the company said.
Six nutrition products including Similac, PediaSure, Ensure, Mama's Best and Glucerna will be manufactured in the Gujarat plant, it added.
Globally, Abbott has presence in more than 150 countries and employs around 69,000 people. In India, it has more than 14,000 employees.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
